Jacques Grill

List of Publications by Year
in descending order

191 papers	12,556 citations	28274 55 h-index	28297 105 g-index
195 all docs	195 docs citations	195 times ranked	11785 citing authors

#	Article	IF	Citations
1	Repurposing Vandetanib plus Everolimus for the Treatment ofACVR1-Mutant Diffuse Intrinsic Pontine Glioma. Cancer Discovery, 2022, 12, 416-431.	9.4	25
2	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. Cancer Discovery, 2022, 12, 712-729.	9.4	15
3	Deciphering the genetic and epigenetic landscape of pediatric bithalamic tumors. Brain Pathology, 2022, 32, e13039.	4.1	5
4	High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2156-e2166.	3.6	6
5	MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 2022, 304, 174-182.	7.3	12
6	HGG-41. Glioma oncogenesis in the constitutional mismatch repair deficiency (CMMRD) syndrome. Neuro-Oncology, 2022, 24, i70-i70.	1.2	0
7	EPEN-24. Biological markers of ependymoma in children and adolescents (BIOMECA): Systematic comparison of methods for the precise evaluation of biomarkers for ependymoma diagnosis and prognostication. Neuro-Oncology, 2022, 24, i44-i44.	1.2	0
8	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
9	HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma. Neuro-Oncology, 2022, 24, i69-i70.	1.2	0
10	NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro-Oncology, 2021, 23, 100-111.	1.2	27
11	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro-Oncology, 2021, 23, 34-43.	1.2	75
12	Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab097.	0.7	5
13	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. Neuro-Oncology Advances, 2021, 3, vdab013.	0.7	27
14	Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features. European Radiology, 2021, 31, 8913-8924.	4.5	11
15	A novel case of cribriform neuroepithelial tumor: A potential diagnostic pitfall in the ventricular system. Pediatric Blood and Cancer, 2021, 68, e29037.	1.5	3
16	A CBF decrease in the left supplementary motor areas: New insight into postoperative pediatric cerebellar mutism syndrome using arterial spin labeling perfusion MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3339-3349.	4.3	10
17	Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta Neuropathologica Communications, 2021, 9, 135.	5.2	21
18	Pediatric brain tumors as a developmental disease. Current Opinion in Oncology, 2021, 33, 608-614.	2.4	2

#	Article	IF	Citations
19	CNS tumors with YWHAE:NUTM2 and KDM2B-fusions present molecular similarities to extra-CNS tumors having BCOR internal tandem duplication or alternative fusions. Acta Neuropathologica Communications, 2021, 9, 176.	5.2	1
20	Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma. Cancers, 2021, 13, 53.	3.7	10
21	Object Detection Improves Tumour Segmentation in MR Images of Rare Brain Tumours. Cancers, 2021, 13, 6113.	3.7	9
22	High Prevalence of Developmental Venous Anomaly in Diffuse Intrinsic Pontine Gliomas: A Pediatric Control Study. Neurosurgery, 2020, 86, 517-523.	1.1	13
23	WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro-Oncology, 2020, 22, 116-127.	1.2	26
24	The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population. Acta Neuropathologica, 2020, 139, 287-303.	7.7	19
25	Regarding â€œNeuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade gliomaâ€. Neuro-Oncology Practice, 2020, 7, 572-573.	1.6	2
26	Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors. Neuron, 2020, 108, 1025-1044.	8.1	31
27	Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma. Neuro-Oncology Advances, 2020, 2, vdaa075.	0.7	2
28	The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of â€œCNS tumors with BCOR internal tandem duplicationâ€. Acta Neuropathologica Communications, 2020, 8, 178.	5.2	17
29	Focal Areas of High Signal Intensity in Children with Neurofibromatosis Type 1: Expected Evolution on MRI. American Journal of Neuroradiology, 2020, 41, 1733-1739.	2.4	8
30	Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. Acta Neuropathologica, 2020, 139, 1109-1113.	7.7	104
31	High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts. Neuro-Oncology, 2020, 22, 1190-1202.	1.2	50
32	Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors. Cancer Letters, 2020, 479, 13-22.	7.2	38
33	Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. Clinical Cancer Research, 2020, 26, 1856-1865.	7.0	10
34	Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children. Neuro-Oncology, 2020, 22, 1686-1695.	1.2	14
35	Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives. Neurosurgical Focus, 2020, 48, E10.	2.3	31
36	A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. Oncogene, 2019, 38, 6479-6490.	5.9	13

#	Article	IF	Citations
37	The dark matter of diffuse intrinsic pontine gliomas: an update. Expert Opinion on Orphan Drugs, 2019, 7, 11-20.	0.8	1
38	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	2.9	36
39	Patients with High-Grade Gliomas and CafÃ©-au-Lait Macules: Is Neurofibromatosis Type 1 the Only Diagnosis?. American Journal of Neuroradiology, 2019, 40, E30-E31.	2.4	4
40	Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. American Journal of Neuroradiology, 2019, 40, 568-575.	2.4	4
41	Anatomo-functional study of the cerebellum in working memory in children treated for medulloblastoma. Journal of Neuroradiology, 2019, 46, 207-213.	1.1	9
42	Constitutional mismatch repair deficiencyâ€“associated brain tumors: report from the European C4CMMRD consortium. Neuro-Oncology Advances, 2019, 1, vdz033.	0.7	23
43	TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG). Clinical Cancer Research, 2019, 25, 6788-6800.	7.0	66
44	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2019, 141, 253-263.	2.9	30
45	Maternal stress and pediatric brain cancer: A French study. Journal of Psychosocial Oncology, 2019, 37, 96-109.	1.2	7
46	Integrated analysis of longâ€term growth and bone development in pediatric and adolescent patients receiving bevacizumab. Pediatric Blood and Cancer, 2019, 66, e27487.	1.5	5
47	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. Brain Pathology, 2019, 29, 325-335.	4.1	55
48	Childhood supratentorial ependymomas with YAP1â€MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathology, 2019, 29, 205-216.	4.1	75
49	CT and Multimodal MR Imaging Features of Embryonal Tumors with Multilayered Rosettes in Children. American Journal of Neuroradiology, 2019, 40, 732-736.	2.4	9
50	Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro-Oncology, 2018, 20, 1122-1132.	1.2	52
51	Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas. Neuro-Oncology, 2018, 20, 994-1002.	1.2	21
52	Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. Journal of Neuroradiology, 2018, 45, 316-322.	1.1	26
53	Coâ€occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathology, 2018, 28, 103-111.	4.1	80
54	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250

#	Article	IF	Citations
55	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. Journal of Clinical Oncology, 2018, 36, 951-958.	1.6	95
56	Transcriptomic and epigenetic profiling of â€˜diffuse midline gliomas, H3 K27M-mutantâ€™ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. Acta Neuropathologica Communications, 2018, 6, 117.	5.2	83
57	DIPG-20. PRE-RANDOMISATION CENTRAL REVIEW AND REAL-TIME BIOMARKERS SCREENING IN THE MULTICENTRE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL: LESSONS LEARNT FROM THE FIRST 120 BIOPSIES. Neuro-Oncology, 2018, 20, i52-i53.	1.2	2
58	Parental stress and paediatric acquired brain injury. Brain Injury, 2018, 32, 1780-1786.	1.2	10
59	Tumor dissemination through surgical tracts in diffuse intrinsic pontine glioma. Journal of Neurosurgery: Pediatrics, 2018, 22, 678-683.	1.3	9
60	New stratification for early childhood medulloblastoma. Pediatric Medicine, 2018, 1, 10-10.	2.7	2
61	Cognitive Profile of Children With Intracranial Germ Cell Tumor According to Tumor Location. Journal of Pediatric Hematology/Oncology, 2018, 40, e424-e428.	0.6	4
62	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. Cancer Cell, 2018, 33, 829-842.e5.	16.8	140
63	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
64	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
65	Diffuse intrinsic pontine gliomasâ€”current management and new biologic insights. Is there a glimmer of hope?. Neuro-Oncology, 2017, 19, 1025-1034.	1.2	91
66	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	16.8	716
67	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clinical Cancer Research, 2017, 23, 6101-6112.	7.0	102
68	Epileptic seizures in anaplastic gangliogliomas. British Journal of Neurosurgery, 2017, 31, 227-233.	0.8	6
69	Relationships between Regional Radiation Doses and Cognitive Decline in Children Treated with Cranio-Spinal Irradiation for Posterior Fossa Tumors. Frontiers in Oncology, 2017, 7, 166.	2.8	20
70	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. PLoS ONE, 2017, 12, e0178351.	2.5	15
71	Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial. Neuro-Oncology Practice, 2017, 4, 161-170.	1.6	9
72	New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. Oncotarget, 2017, 8, 52543-52559.	1.8	41

#	Article	IF	Citations
73	HG-46RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMAS: CLINICAL, BIOLOGICAL, RADIOLOGICAL AND THERAPEUTIC FACTORS CORRELATING WITH THE SURVIVAL. Neuro-Oncology, 2016, 18, iii57.4-iii58.	1.2	0
74	Primary Leptomeningeal Gliomatosis in Children and Adults. Neurosurgery, 2016, 78, 343-352.	1.1	10
75	Chordoma in children: Case-report and review of literature. Reports of Practical Oncology and Radiotherapy, 2016, 21, 1-7.	0.6	11
76	Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas. American Journal of Neuroradiology, 2016, 37, 1581-1587.	2.4	31
77	Histone H3 genotyping refines clinico-radiological diagnostic and prognostic criteria in DIPG. Acta Neuropathologica, 2016, 131, 795-796.	7.7	11
78	Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma. Journal of Neuropathology and Experimental Neurology, 2016, 75, 971-980.	1.7	54
79	Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. SpringerPlus, 2016, 5, 879.	1.2	35
80	Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. British Journal of Clinical Pharmacology, 2016, 81, 148-160.	2.4	38
81	Arterial Spin Labeling to Predict Brain Tumor Grading in Children: Correlations between Histopathologic Vascular Density and Perfusion MR Imaging. Radiology, 2016, 281, 553-566.	7.3	82
82	Reprint of â€œChordoma in children: Case-report and review of literatureâ€• Reports of Practical Oncology and Radiotherapy, 2016, 21, 412-417.	0.6	4
83	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
84	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
85	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. Neuro-Oncology, 2016, 18, 582-588.	1.2	25
86	Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. Annals of Clinical and Translational Neurology, 2015, 2, 439-443.	3.7	51
87	Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy. Journal of Pediatric Hematology/Oncology, 2015, 37, e102-e110.	0.6	31
88	Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy. PLoS ONE, 2015, 10, e0127676.	2.5	38
89	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro-Oncology, 2015, 17, 1486-1496.	1.2	39
90	A common polymorphism in the 5â€² UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. Genes and Development, 2015, 29, 1891-1896.	5.9	32

#	Article	IF	Citations
91	Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro-Oncology, 2015, 17, 953-964.	1.2	56
92	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
93	Inhibition of the NOTCH pathway using Î³-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. Anti-Cancer Drugs, 2015, 26, 272-283.	1.4	26
94	Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathologica, 2015, 130, 815-827.	7.7	482
95	Translating preclinical hopes into clinical reality for children with ependymoma. Neuro-Oncology, 2015, 17, 1545-1546.	1.2	1
96	Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Child's Nervous System, 2015, 31, 1773-1780.	1.1	145
97	Conceptions of time in children treated for malignant cerebellar tumours. Brain Injury, 2014, 28, 1334-1341.	1.2	3
98	Variable selection for generalized canonical correlation analysis. Biostatistics, 2014, 15, 569-583.	1.5	168
99	Water and Electrolyte Disorders at Long-Term Post-Treatment Follow-Up in Paediatric Patients with Suprasellar Tumours Include Unexpected Persistent Cerebral Salt-Wasting Syndrome. Hormone Research in Paediatrics, 2014, 82, 364-371.	1.8	20
100	Vemurafenib in pediatric patients with <scp>BRAFV</scp>600E mutated highâ€grade gliomas. Pediatric Blood and Cancer, 2014, 61, 1101-1103.	1.5	125
101	Central nervous system germ cell tumors. Current Opinion in Oncology, 2014, 26, 622-626.	2.4	26
102	Tandem highâ€dose chemotherapy and autologous stem cell rescue in children with newly diagnosed highâ€risk medulloblastoma or supratentorial primitive neuroâ€ectodermic tumors. Pediatric Blood and Cancer, 2014, 61, 1398-1402.	1.5	46
103	Highâ€dose busulfanâ€“thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 907-912.	1.5	18
104	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 294-307.	7.4	45
105	Stability of medulloblastoma subgroups at tumour recurrence. Nature Reviews Neurology, 2014, 10, 5-6.	10.1	4
106	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	28.4	469
107	Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 383-386.	1.5	33
108	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	21.4	423

#	Article	IF	Citations
109	Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. Drugs in R and D, 2014, 14, 13-23.	2.2	4
110	Disrupted sensorimotor synchronization, but intact rhythm discrimination, in children treated for a cerebellar medulloblastoma. Research in Developmental Disabilities, 2014, 35, 2053-2068.	2.2	14
111	A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. Journal of Neuro-Oncology, 2013, 113, 127-134.	2.9	9
112	Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases. Child's Nervous System, 2013, 29, 565-571.	1.1	13
113	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncology, 2013, 15, 1236-1243.	1.2	41
114	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	16.8	633
115	Time perception in children treated for a cerebellar medulloblastoma. Research in Developmental Disabilities, 2013, 34, 480-494.	2.2	12
116	Impact of extensive surgery in multidisciplinary approach of pterygopalatine/infratemporal fossa soft tissue sarcoma. Pediatric Blood and Cancer, 2013, 60, 928-934.	1.5	9
117	Current and evolving knowledge of prognostic factors for pediatric ependymomas. Future Oncology, 2013, 9, 183-191.	2.4	13
118	Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clinical Cancer Research, 2012, 18, 2001-2011.	7.0	111
119	Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits. Lancet Oncology, The, 2012, 13, e445-e459.	10.7	134
120	Teachersâ€™ report of learning and behavioural difficulties in children treated for cerebellar tumours. Brain Injury, 2012, 26, 1014-1020.	1.2	21
121	Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival. Neuro-Oncology, 2012, 14, 1413-1421.	1.2	14
122	Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas. PLoS ONE, 2012, 7, e30313.	2.5	200
123	Long Time to Diagnosis of Medulloblastoma in Children Is Not Associated with Decreased Survival or with Worse Neurological Outcome. PLoS ONE, 2012, 7, e33415.	2.5	34
124	Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatric Blood and Cancer, 2012, 58, 489-491.	1.5	111
125	Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system. Cancer, 2012, 118, 3812-3821.	4.1	101
126	Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2012, 106, 399-407.	2.9	100

#	Article	IF	Citations
127	Interval between onset of symptoms and diagnosis of medulloblastoma in children: distribution and determinants in a population-based study. European Journal of Pediatrics, 2012, 171, 25-32.	2.7	39
128	Neuropathological and Neuroradiological Spectrum of Pediatric Malignant Gliomas: Correlation With Outcome. Neurosurgery, 2011, 69, 215-224.	1.1	11
129	Pediatric ependymomas. Current Opinion in Oncology, 2011, 23, 638-642.	2.4	9
130	Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institutionâ€™s experience. Journal of Neuro-Oncology, 2011, 104, 773-777.	2.9	48
131	Cerebellar mutism: definitions, classification and grading of symptoms. Child's Nervous System, 2011, 27, 1361-1363.	1.1	35
132	Appraisal of the current staging system for residual medulloblastoma by volumetric analysis. Child's Nervous System, 2011, 27, 2101-2106.	1.1	6
133	Atypical teratoid rhabdoid tumor mimicking beta-catenin-positive nodular medulloblastoma. Acta Neuropathologica, 2011, 121, 429-430.	7.7	3
134	Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality. Brain, 2011, 134, 1362-1372.	7.6	60
135	Clinical Relevance of Tumor Cells with Stem-Like Properties in Pediatric Brain Tumors. PLoS ONE, 2011, 6, e16375.	2.5	57
136	Utility of Cerebrospinal Fluid Cytology in Newly Diagnosed Childhood Ependymoma. Journal of Pediatric Hematology/Oncology, 2010, 32, 515-518.	0.6	10
137	Medulloblastoma in young children. Pediatric Blood and Cancer, 2010, 54, 635-637.	1.5	52
138	Portrait of Ependymoma Recurrence in Children: Biomarkers of Tumor Progression Identified by Dual-Color Microarray-Based Gene Expression Analysis. PLoS ONE, 2010, 5, e12932.	2.5	35
139	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. Journal of Clinical Oncology, 2010, 28, 4961-4968.	1.6	273
140	Low Bone Mineral Density and High Incidences of Fractures and Vitamin D Deficiency in 52 Pediatric Cancer Survivors. Hormone Research in Paediatrics, 2010, 74, 319-327.	1.8	33
141	Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro-Oncology, 2010, 12, 1126-1134.	1.2	54
142	Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. Journal of Medical Genetics, 2010, 47, 142-144.	3.2	51
143	Forniceal glioma in children. Journal of Neurosurgery: Pediatrics, 2009, 4, 249-253.	1.3	5
144	Online Quality Control, Hyperfractionated Radiotherapy Alone and Reduced Boost Volume for Standard Risk Medulloblastoma: Long-Term Results of MSFOP 98. Journal of Clinical Oncology, 2009, 27, 1879-1883.	1.6	79

#	Article	IF	Citations
145	Injuries to inferior vermis and dentate nuclei predict poor neurological and neuropsychological outcome in children with malignant posterior fossa tumors. Cancer, 2009, 115, 1338-1347.	4.1	118
146	Astrocytes Reverted to a Neural Progenitor-like State with Transforming Growth Factor Alpha Are Sensitized to Cancerous Transformation. Stem Cells, 2009, 27, 2373-2382.	3.2	39
147	Relapses of optic pathway tumors after firstâ€line chemotherapy. Pediatric Blood and Cancer, 2009, 52, 575-580.	1.5	16
148	Cognitive and Academic Outcome After Benign or Malignant Cerebellar Tumor in Children. Cognitive and Behavioral Neurology, 2009, 22, 270-278.	0.9	32
149	Do medulloblastoma tumors meet the food and drug administration criteria for anti-erbB2 therapy with trastuzumab?. Pediatric Blood and Cancer, 2008, 50, 163-166.	1.5	5
150	Metastatic ependymoma: A multiâ€institutional retrospective analysis of prognostic factors. Pediatric Blood and Cancer, 2008, 50, 231-235.	1.5	59
151	Intracerebral small round cell tumor: An unusual case with EWSâ€WT1 translocation. Pediatric Blood and Cancer, 2008, 51, 545-548.	1.5	13
152	EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. International Journal of Cancer, 2008, 123, 209-216.	5.1	56
153	Medulloblastoma: what is the role of molecular genetics?. Expert Review of Anticancer Therapy, 2008, 8, 1169-1181.	2.4	13
154	Treatment-related Myelodysplastic Syndrome After Temozolomide Use in a Child. Journal of Pediatric Hematology/Oncology, 2008, 30, 857-859.	0.6	12
155	Thalamic tumors in children: a reappraisal. Journal of Neurosurgery: Pediatrics, 2007, 106, 354-362.	1.3	75
156	Stereotactic biopsy of diffuse pontine lesions in children. Journal of Neurosurgery: Pediatrics, 2007, 107, 1-4.	1.3	126
157	Pediatric infratentorial gangliogliomas: a retrospective series. Journal of Neurosurgery: Pediatrics, 2007, 107, 286-291.	1.3	27
158	Recent development in chemotherapy of paediatric brain tumours. Current Opinion in Oncology, 2007, 19, 612-615.	2.4	20
159	Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. Journal of Neurosurgery: Pediatrics, 2007, 106, 3-12.	1.3	225
160	High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer, 2007, 110, 156-163.	4.1	58
161	High-dose chemotherapy in children with newly-diagnosed medulloblastoma. Lancet Oncology, The, 2006, 7, 787-789.	10.7	22
162	p53 pathway dysfunction in primary childhood ependymomas. Pediatric Blood and Cancer, 2006, 46, 604-613.	1.5	30

#	Article	IF	Citations
163	Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genetics and Cytogenetics, 2006, 166, 74-81.	1.0	67
164	StratÃ©gies de prise en charge nutritionnelle spÃ©cifiquesÂ: l'enfant en cancÃ©rologie. Nutrition Clinique Et Metabolisme, 2005, 19, 234-237.	0.5	3
165	Craniopharyngioma: the pendulum of surgical management. Child's Nervous System, 2005, 21, 691-695.	1.1	129
166	The Therapy of Infantile Malignant Brain Tumors: Current Status?. Journal of Neuro-Oncology, 2005, 75, 279-285.	2.9	69
167	Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors. Pediatric Blood and Cancer, 2005, 45, 814-819.	1.5	49
168	Oncolytic Virotherapy of Meningiomas in Vitro with Replication-competent Adenovirus. Neurosurgery, 2005, 56, 146-154.	1.1	5
169	Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study. Journal of Neurosurgery: Pediatrics, 2005, 103, 312-318.	1.3	13
170	Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncology, The, 2005, 6, 573-580.	10.7	250
171	Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus Adî”24-p53 against Human Malignant Glioma. Cancer Research, 2004, 64, 5753-5759.	0.9	64
172	Measuring the neuro-cognitive side-effects of irradiation in children with brain tumors. Pediatric Blood and Cancer, 2004, 42, 452-456.	1.5	25
173	Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. Journal of Neurosurgery: Pediatrics, 2004, 101, 152-158.	1.3	67
174	In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts. Cancer Chemotherapy and Pharmacology, 2003, 51, 385-394.	2.3	18
175	Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapyâ€”Results of the First French Prospective Study for the French Society of Pediatric Oncology. Journal of Clinical Oncology, 2003, 21, 4572-4578.	1.6	167
176	Childhood Ependymoma. Paediatric Drugs, 2003, 5, 533-543.	3.1	38
177	Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients. Brain, 2003, 126, 152-160.	7.6	242
178	Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished. Journal of Virology, 2002, 76, 2753-2762.	3.4	88
179	Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genetics and Cytogenetics, 2002, 136, 121-125.	1.0	57
180	Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Research, 2002, 62, 764-72.	0.9	89

#	Article	IF	Citations
181	Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Research, 2002, 62, 5736-42.	0.9	142
182	The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Molecular Therapy, 2002, 6, 609-14.	8.2	37
183	Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Research, 2002, 62, 6165-71.	0.9	104
184	Adjuvant Chemotherapy for Ependymoma: Is It Necessary for All Children Under Five Years of Age?. Journal of Clinical Oncology, 2001, 19, 3588-3589.	1.6	2
185	Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology. Journal of Clinical Oncology, 2001, 19, 1288-1296.	1.6	258
186	Visual Agnosia After Treatment of a Posterior Fossa Ependymoma in a 16-Month-Old Girl. Journal of Child Neurology, 2001, 16, 698-704.	1.4	7
187	Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Therapy, 2000, 7, 901-904.	4.6	145
188	When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. European Journal of Pediatrics, 2000, 159, 692-696.	2.7	113
189	Patterns of neuropsychological deficits in children with medulloblastoma according to craniospatial irradiation doses. Developmental Medicine and Child Neurology, 2000, 42, 741-745.	2.1	102
190	High-dose chemotherapy in childhood brain tumours. Child's Nervous System, 1999, 15, 498-505.	1.1	38
191	Pneumomediastinum: A rare, impressive but benign complication of chemotherapy-induced emesis in children. , 1998, 31, 182-184.		5